Loading
Dutch paediatric oncologist who led the international Interfant trials for babies with leukaemia and helped create the Princess Máxima Center, which brought all Dutch childhood cancer care into one hospital.
Rob Pieters is a paediatric oncologist and the founding chief medical officer of the Princess Máxima Center in Utrecht, which since 2018 has treated all children with cancer in the Netherlands. He chaired the Interfant-99 and Interfant-06 international trials for infants with acute lymphoblastic leukaemia and was first author of their reports in the Lancet (2007) and Journal of Clinical Oncology (2019), which defined the standard hybrid chemotherapy for this high-risk group and showed that early intensification did not improve outcomes.
| Title | Journal | Year |
|---|---|---|
| Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia | Journal of Clinical Oncology | 2019 |
| Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia | The Lancet | 2007 |
Interfant-06 is the backbone and control benchmark for infant ALL; the successor Interfant-21 adds blinatumomab after this trial showed chemotherapy intensification had reached its limit.
Interfant-99 defined the risk groups and backbone used in Interfant-06 and Interfant-21.
Shares Princess Máxima Center for Pediatric Oncology, Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Childhood cancers (all types), Acute lymphoblastic leukaemia and the tags paediatric, leukaemia, trialist.
Shares Childhood cancers (all types), Acute lymphoblastic leukaemia and the tags paediatric, leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares the tags leukaemia, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.
Shares Childhood cancers (all types) and the tags paediatric, trialist.